Active Filter(s):
Details:
Under the collaboration, PharmaTher will be responsible for regulatory, manufacturing and supply of Ketarx (ketamine hydrochloride), an FDA-approved NMDA receptor-modulating drug, and Vitruvias will be responsible for the marketing, sales, and distribution in the U.S. market.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Ketarx
Highest Development Status: Phase III Product Type: Small molecule
Recipient: PharmaTher
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 20, 2023